Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Vera Therapeutics, Inc. (VERA)

31.07 +1.08 (+3.60%)
As of 10:51:36 AM EDT. Market Open.
Trade VERA on Coinbase
Chart Range Bar
Loading chart for VERA
  • Previous Close 29.99
  • Open 29.77
  • Bid 22.14 x 100
  • Ask 38.91 x 200
  • Day's Range 29.77 - 31.13
  • 52 Week Range 23.05 - 56.05
  • Volume 478,163
  • Avg. Volume 2,156,107
  • Market Cap (intraday) 2.239B
  • Beta (5Y Monthly) 1.05
  • PE Ratio (TTM) --
  • EPS (TTM) -5.87
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 74.20
  • Zacks Rating Neutral

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

veratx.com

361

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VERA
38.65%
S&P 500 (^GSPC)
12.89%

1-Year Return

VERA
3.70%
S&P 500 (^GSPC)
12.15%

3-Year Return

VERA
211.32%
S&P 500 (^GSPC)
87.69%

5-Year Return

VERA
76.13%
S&P 500 (^GSPC)
68.13%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -109.47M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-120M
-100M
-80M
-60M
-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

34.00
74.20 Average
31.07 Current
100.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/12/2026
Analyst Leerink Partners
Rating Action Initiated
Rating Market Perform
Price Action Announces
Price Target 34

Statistics

View More

Valuation Measures

Annual
As of 10/26/2026
  • Market Cap

    2.04B

  • Enterprise Value

    1.62B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.99

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -46.76%

  • Return on Equity (ttm)

    -91.75%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -401.9M

  • Diluted EPS (ttm)

    -5.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    499.16M

  • Total Debt/Equity (mrq)

    18.86%

  • Levered Free Cash Flow (ttm)

    -212.95M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

31.07 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: